ResearcherShizuoka Cancer CenterActive in the last 2 years
Keiichi Ohshima
Matched on ORCID iD 0000-0002-2882-7566; OpenAlex author ID A5078599913. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 3 papers
Papers 7
- Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy. Co-author DOI 10.1097/sla.0000000000007152↗
- Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. Co-author DOI 10.1245/s10434-025-18556-3↗
- ASO Author Reflections: Genomic Features of Familial and Sporadic Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18624-8↗
- Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. Co-author DOI 10.1093/bjs/znae059↗
- Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. Co-author DOI 10.1002/ags3.12636↗
- Characterization of pancreatic cancer with ultra-low tumor mutational burden. Co-author DOI 10.1038/s41598-023-31579-8↗
- Comparative proteomic analysis identifies exosomal Eps8 protein as a potential metastatic biomarker for pancreatic cancer. Co-author DOI 10.3892/or.2018.6869↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Teiichi Sugiura · 6 shared papers, 2023–2026 · strength 1.36
- Paper ASO Author Reflections: Genomic Features of Familial and Sporadic Pancreatic Cancer. DOI 10.1245/s10434-025-18624-8↗
- Paper Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. DOI 10.1245/s10434-025-18556-3↗
- Paper Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperativ… DOI 10.1097/sla.0000000000007152↗
- Yukiyasu Okamura · 5 shared papers, 2023–2026 · strength 1.20
- Paper ASO Author Reflections: Genomic Features of Familial and Sporadic Pancreatic Cancer. DOI 10.1245/s10434-025-18624-8↗
- Paper Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. DOI 10.1245/s10434-025-18556-3↗
- Paper Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperativ… DOI 10.1097/sla.0000000000007152↗
- Ryo Ashida · 5 shared papers, 2023–2026 · strength 1.00
- Paper Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. DOI 10.1245/s10434-025-18556-3↗
- Paper Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperativ… DOI 10.1097/sla.0000000000007152↗
- Paper Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. DOI 10.1093/bjs/znae059↗
- Katsuhiko Uesaka · 5 shared papers, 2023–2026 · strength 1.00
- Paper Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. DOI 10.1245/s10434-025-18556-3↗
- Paper Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperativ… DOI 10.1097/sla.0000000000007152↗
- Paper Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. DOI 10.1093/bjs/znae059↗
- Katsuhisa Ohgi · 5 shared papers, 2023–2026 · strength 1.00
- Paper Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. DOI 10.1245/s10434-025-18556-3↗
- Paper Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperativ… DOI 10.1097/sla.0000000000007152↗
- Paper Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. DOI 10.1093/bjs/znae059↗
- Yuya Miura · 3 shared papers, 2026 · strength 0.84
- Paper ASO Author Reflections: Genomic Features of Familial and Sporadic Pancreatic Cancer. DOI 10.1245/s10434-025-18624-8↗
- Paper Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. DOI 10.1245/s10434-025-18556-3↗
- Paper Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperativ… DOI 10.1097/sla.0000000000007152↗
- Kenichi Urakami · 4 shared papers, 2023–2026 · strength 0.83
- Paper Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. DOI 10.1245/s10434-025-18556-3↗
- Paper Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperativ… DOI 10.1097/sla.0000000000007152↗
- Paper Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. DOI 10.1093/bjs/znae059↗
- Taisuke Imamura · 3 shared papers, 2023–2024 · strength 0.52
- Paper Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. DOI 10.1093/bjs/znae059↗
- Paper Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. DOI 10.1002/ags3.12636↗
- Paper Characterization of pancreatic cancer with ultra-low tumor mutational burden. DOI 10.1038/s41598-023-31579-8↗
- Ken D Yamaguchi · 2 shared papers, 2024–2026 · strength 0.43
- Ken Yamaguchi · 3 shared papers, 2019–2023 · strength 0.43
- Paper Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. DOI 10.1002/ags3.12636↗
- Paper Characterization of pancreatic cancer with ultra-low tumor mutational burden. DOI 10.1038/s41598-023-31579-8↗
- Paper Comparative proteomic analysis identifies exosomal Eps8 protein as a potential metastatic biomarker for pancreatic canc… DOI 10.3892/or.2018.6869↗
- Mihoko Yamada · 2 shared papers, 2023–2024 · strength 0.34
- Yoshiyasu Kato · 1 shared paper, 2026 · strength 0.24
- Takumi Kitahama · 1 shared paper, 2026 · strength 0.24
- Tohru Mochizuki · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.